Truist raised the firm’s price target on Stryker (SYK) to $400 from $390 and keeps a Hold rating on the shares. The company delivered another double-digit organic sales and EPS growth performance despite an incremental $200M in tariff headwinds, the analyst tells investors in a research note. Stryker also boasts a premium revenue growth profile in large-cap MedTech, with several new launch areas set to build momentum, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker price target raised to $450 from $440 at Bernstein
- Stryker’s Strong Performance and Growth Potential Justify Buy Rating
- Stryker Corp’s Earnings Call Highlights Robust Growth
- Stryker price target raised to $456 from $405 at Roth Capital
- Stryker’s Strong Financial Performance and Strategic Positioning Justify Buy Rating